These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33712363)

  • 1. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
    Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case-control study.
    Pan CH; Chien SC; Chen CJ; Shih CM; Hsieh MH; Huang CY; Bi WF; Chan CS; Kao YT; Hsiao CY; Chiang SJ; Chiang KH; Huang JH; Liu YR; Luo JD; Huang HY; Wu CH
    BMC Cardiovasc Disord; 2021 Feb; 21(1):77. PubMed ID: 33557763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of high level of hs-CRP with in-stent restenosis: A case-control study.
    Baktashian M; Saffar Soflaei S; Kosari N; Salehi M; Khosravi A; Ahmadinejad M; Moohebati M; Ebrahimi M; Rahmani F; Khameneh-Bagheri R; Ahmadi M; Sadabadi F; Tayefi M; Bazhdanzadeh S; Ferns GA; Hashemi SM; Pasdar A; Ghayour-Mobarhan M
    Cardiovasc Revasc Med; 2019 Jul; 20(7):583-587. PubMed ID: 30232022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
    Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
    Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis.
    He M; Gong Y; Shi J; Pan Z; Zou H; Sun D; Tu X; Tan X; Li J; Li W; Liu B; Xue J; Sheng L; Xiu C; Yang N; Xue H; Ding X; Yu C; Li Y
    PLoS One; 2014; 9(11):e112043. PubMed ID: 25427155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
    He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention.
    Dai R; Liu Y; Zhou Y; Xiong X; Zhou W; Li W; Zhou W; Chen M
    J Clin Lab Anal; 2020 Jan; 34(1):e23013. PubMed ID: 31495986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of plasma Quaking and cyclooxygenase-2 predict in-stent restenosis in patients with coronary artery disease after percutaneous coronary intervention.
    Wang P; Kuang Y; Liu Y; Zhang Y; Gao H; Ma Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):739-747. PubMed ID: 35837773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visit-to-visit HbA
    Yang CD; Shen Y; Lu L; Yang ZK; Hu J; Zhang RY; Shen WF; Ding FH; Wang XQ
    Cardiovasc Diabetol; 2020 Sep; 19(1):133. PubMed ID: 32887588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease.
    Dong J; Liang YZ; Zhang J; Wu LJ; Wang S; Hua Q; Yan YX
    J Atheroscler Thromb; 2017 Apr; 24(4):430-441. PubMed ID: 27629254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography.
    Wan YL; Tsay PK; Chen CC; Juan YH; Huang YC; Chan WH; Wen MS; Hsieh IC
    Int J Cardiovasc Imaging; 2016 Jun; 32 Suppl 1():105-15. PubMed ID: 27106698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.